Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Athira Pharma (ATHA)
NASDAQ:ATHA
Athira Pharma (ATHA) Stock Price & Analysis
485 Followers
ATHA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.33 - $4.30
Previous Close$2.55
Volume31.70K
Average Volume (3M)146.38K
Market Cap
$97.74M
Enterprise Value-$22.85M
Total Cash (Recent Filing)$122.09M
Total Debt (Recent Filing)$1.50M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Aug 12, 2024EPS Estimate
-$0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.05
Shares Outstanding38,328,652
10 Day Avg. Volume127,172
30 Day Avg. Volume146,383
Standard Deviation0.26
R-Squared0.32
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.84
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.26
Forecast
1Y Price Target
$11.33Price Target Upside344.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Athira Pharma News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPositive interim analysis results from LIFT-AD are viewed as a de-risking event for fosgonimeton, indicating its potential clinically meaningful activity in patients without background therapy.
Drug MechanismFosgo can positively modulate the neurotrophic HGF/MET system for the promotion of neuronal repair and function, achieving symptomatic and disease-modifying effects in patients with Alzheimer's disease.
Investor ConfidenceInvestor event provided insights into the Global Statistical Test primary endpoint in LIFT-AD that bolster confidence in positive results, potentially boosting investor interest.
Bears Say
Investor ConfidenceThe stock still shows little investor confidence in the LIFT-AD readout despite the positive interim look.
Regulatory ApprovalThe company expects it will need to conduct an additional Ph3 study ahead of seeking registrational approval for fosgo, given safety database requirements in AD.
Scientific ChallengesThe pathology of ALS is complex and particularly challenging for drug development.
---
Ownership Overview
31.48% Insiders
8.50% Mutual Funds
47.87% Other Institutional Investors
12.14% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ATHA FAQ
What was Athira Pharma’s price range in the past 12 months?
Athira Pharma lowest stock price was $1.33 and its highest was $4.30 in the past 12 months.
What is Athira Pharma’s market cap?
Currently, no data Available
When is Athira Pharma’s upcoming earnings report date?
Athira Pharma’s upcoming earnings report date is Aug 12, 2024 which is in 37 days.
How were Athira Pharma’s earnings last quarter?
Athira Pharma released its earnings results on May 15, 2024. The company reported -$0.69 earnings per share for the quarter, beating the consensus estimate of -$0.799 by $0.109.
Is Athira Pharma overvalued?
According to Wall Street analysts Athira Pharma’s price is currently Undervalued.
Does Athira Pharma pay dividends?
Athira Pharma does not currently pay dividends.
What is Athira Pharma’s EPS estimate?
Athira Pharma’s EPS estimate is -$0.74.
How many shares outstanding does Athira Pharma have?
Athira Pharma has 38,328,650 shares outstanding.
What happened to Athira Pharma’s price movement after its last earnings report?
Athira Pharma reported an EPS of -$0.69 in its last earnings report, beating expectations of -$0.799. Following the earnings report the stock price went up 22.624%.
Which hedge fund is a major shareholder of Athira Pharma?
Among the largest hedge funds holding Athira Pharma’s share is Perceptive Advisors LLC. It holds Athira Pharma’s shares valued at 15M.
---
Athira Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.33 (344.31% Upside)
$11.33 (344.31% Upside)
Insider Transactions
Bought Shares
Worth $99.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.89%
12-Months-Change
Fundamentals
Return on Equity
-73.11%
Trailing 12-Months
Asset Growth
-42.67%
Trailing 12-Months
Company Description
Athira Pharma
Athira Pharma Inc is a bio-technology company focused on developing small molecules to restore neuronal health and stop neurodegeneration. The company is developing treatments for Alzheimer's disease and Parkinson's disease.
---
ATHA Stock 12 Month Forecast
Average Price Target
$11.33
▲(344.31% Upside)
Technical Analysis
Best Analysts Covering ATHA
1 Year
1 Year Success Rate
3/15 ratings generated profit
1 Year Average Return
-12.86%
reiterated a buy rating 17 days ago
Copying Graig Suvannavejh's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -12.86% per trade.
---